SG11201900133WA - Adrenomedullin for assessing congestion in a subject with acute heart failure - Google Patents

Adrenomedullin for assessing congestion in a subject with acute heart failure

Info

Publication number: SG11201900133WA
Authority: SG; Singapore
Prior art keywords: subject; congestion; international; intervention; heart failure
Prior art date: 2016-07-08

Application number

SG11201900133WA

Other languages

English (en)

Inventor

Andreas Bergmann

Adriaan Voors

Original Assignee

Sphingotec Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-07-08

Filing date

2017-07-07

Publication date

2019-02-27

2017-07-07 Application filed by Sphingotec Gmbh filed Critical Sphingotec Gmbh

2019-02-27 Publication of SG11201900133WA publication Critical patent/SG11201900133WA/en

Links

206010007556 Cardiac failure acute Diseases 0.000 title abstract 3
102000004379 Adrenomedullin Human genes 0.000 title abstract 2
101800004616 Adrenomedullin Proteins 0.000 title abstract 2
ULCUCJFASIJEOE-NPECTJMMSA-N adrenomedullin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H]1C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)[C@@H](C)O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 ULCUCJFASIJEOE-NPECTJMMSA-N 0.000 title abstract 2
238000002560 therapeutic procedure Methods 0.000 abstract 5
238000012544 monitoring process Methods 0.000 abstract 3
206010007558 Cardiac failure chronic Diseases 0.000 abstract 2
230000001154 acute effect Effects 0.000 abstract 2
239000003795 chemical substances by application Substances 0.000 abstract 2
150000001413 amino acids Chemical class 0.000 abstract 1
230000001684 chronic effect Effects 0.000 abstract 1
239000012634 fragment Substances 0.000 abstract 1
239000003550 marker Substances 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
230000008520 organization Effects 0.000 abstract 1
102000034567 proadrenomedullin Human genes 0.000 abstract 1
108010012004 proadrenomedullin Proteins 0.000 abstract 1
208000024891 symptom Diseases 0.000 abstract 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Food Science & Technology (AREA)
Cell Biology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Biotechnology (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Organic Chemistry (AREA)
Endocrinology (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Cardiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Heart & Thoracic Surgery (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Investigating Or Analysing Biological Materials (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

SG11201900133WA 2016-07-08 2017-07-07 Adrenomedullin for assessing congestion in a subject with acute heart failure SG11201900133WA (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP16178725		2016-07-08
EP16199092		2016-11-16
PCT/EP2017/067091 WO2018007588A1 (fr)	2016-07-08	2017-07-07	Adrénomédulline pour évaluation de la congestion chez un sujet atteint d'insuffisance cardiaque aiguë

Publications (1)

Publication Number	Publication Date
SG11201900133WA true SG11201900133WA (en)	2019-02-27

Family

ID=59366410

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201900133WA SG11201900133WA (en)	2016-07-08	2017-07-07	Adrenomedullin for assessing congestion in a subject with acute heart failure

Country Status (12)

Country	Link
US (1)	US20190376985A1 (fr)
EP (2)	EP3482208B1 (fr)
JP (3)	JP7191813B2 (fr)
CN (1)	CN109716136B (fr)
AU (1)	AU2017294549C1 (fr)
BR (1)	BR112019000199A2 (fr)
CA (1)	CA3030214A1 (fr)
ES (1)	ES2948446T3 (fr)
MX (1)	MX2019000003A (fr)
RU (1)	RU2019103403A (fr)
SG (1)	SG11201900133WA (fr)
WO (1)	WO2018007588A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3438668A1 (fr)	2017-08-04	2019-02-06	B.R.A.H.M.S GmbH	Diagnostic et stratification des risques d'infections fongiques
JP7346389B2 (ja)	2017-09-13	2023-09-19	ベー．エル．アー．ハー．エム．エスゲゼルシャフトミットベシュレンクテルハフツング	異常な血小板レベルのマーカーとしてのプロアドレノメジュリン
EP3502706A1 (fr)	2017-12-20	2019-06-26	B.R.A.H.M.S GmbH	Workflow pour l'évaluation du risque et la gestion de patients à l'aide de la procalcitonine et de la proadrénoméduline midrégionale
AU2019219071A1 (en) *	2018-02-08	2020-07-30	Sphingotec Gmbh	Adrenomedullin (ADM) for diagnosis and/or prediction of dementia and anti-adrenomedullin binder for use in therapy or prevention of dementia
EP3608673A1 (fr) *	2018-08-08	2020-02-12	B.R.A.H.M.S GmbH	Pro-adm pour pronostiquer le risque d'une condition médicale nécessitant une hospitalisation chez des patients présentant des symptômes d'une maladie infectieuse
EP4023218A1 (fr)	2020-12-02	2022-07-06	S-Form Pharma	Thérapie combinée pour les patients souffrant d'une dyspnée aiguë et/ou persistante

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5807715A (en)	1984-08-27	1998-09-15	The Board Of Trustees Of The Leland Stanford Junior University	Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
AU634716B2 (en)	1988-08-01	1993-03-04	Ciba Corning Diagnostics Corp.	Method for detection of an analyte using acridinium esters and liposomes
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
DE69120146T2 (de)	1990-01-12	1996-12-12	Cell Genesys Inc	Erzeugung xenogener antikörper
US5427908A (en)	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
DK0585287T3 (da)	1990-07-10	2000-04-17	Cambridge Antibody Tech	Fremgangsmåde til fremstilling af specifikke bindingsparelementer
EP0746609A4 (fr)	1991-12-17	1997-12-17	Genpharm Int	Animaux transgeniques non humains capables de produire des anticorps heterologues
JP2774769B2 (ja)	1993-04-26	1998-07-09	賢治寒川	アドレノメデュリン
US6818418B1 (en)	1998-12-10	2004-11-16	Compound Therapeutics, Inc.	Protein scaffolds for antibody mimics and other binding proteins
NZ531207A (en)	2001-08-30	2006-08-31	Biorexis Pharmaceutical Corp	Modified transferrin fusion proteins to extend the serum half-life or bioavailability of the molecule
DK1531791T3 (da)	2002-06-07	2010-11-01	Dyax Corp	Forebyggelse og begrænsning af iskæmi
AU2004284090A1 (en)	2003-10-24	2005-05-06	Avidia, Inc.	LDL receptor class A and EGF domain monomers and multimers
US20100028995A1 (en)	2004-02-23	2010-02-04	Anaphore, Inc.	Tetranectin Trimerizing Polypeptides
WO2006032436A2 (fr)	2004-09-21	2006-03-30	Nascacell Technologies Ag.	Utilisation de microproteines en tant qu'inhibiteurs d'une tryptase
US9012151B2 (en) *	2006-11-09	2015-04-21	B.R.A.H.M.S. Gmbh	Methods of diagnosis and risk stratification of adverse events in post myocardial infarction patients using pro-adrenomedullin
DE102006060112A1 (de)	2006-12-20	2008-06-26	Brahms Aktiengesellschaft	Diagnose und Risikostratifizierung mittels dem neuen Marker CT-proADM
ES2373832T3 (es)	2007-12-19	2012-02-09	Affibody Ab	Polipéptido derivado de proteína a y capaz de unirse a pdgf.
CN107011425B (zh)	2008-11-03	2021-01-01	分子组合公司	抑制vegf-a受体相互作用的结合蛋白
JP5584695B2 (ja) *	2008-11-11	2014-09-03	ベー．エル．アー．ハー．エム．エスゲゼルシャフトミットベシュレンクテルハフツング	Ａｄｍ及びｂｎｐのレベルを決定することによる心疾患に罹患した患者の予後診断及びリスク評価
WO2010128071A1 (fr) *	2009-05-05	2010-11-11	Brahms Ag	Stratification à base d'hormone vasoactive de patients souffrant de maladies liées à la fonction ou à un dysfonctionnement endothélial
NZ598351A (en)	2009-08-27	2014-08-29	Covagen Ag	Il-17 binding compounds and medical uses thereof
AU2010332938B2 (en)	2009-12-14	2012-12-20	Navigo Proteins Gmbh	A method for identifying hetero-multimeric modified ubiquitin proteins with binding capability to ligands
CN105949301B (zh)	2010-06-08	2020-03-27	皮里斯制药有限公司	结合IL-4受体α的泪脂质运载蛋白突变蛋白
ES2494191T3 (es) *	2011-11-16	2014-09-15	Adrenomed Ag	Anticuerpo anti-adrenomedulina (ADM) o fragmento de anticuerpo anti-ADM o andamiaje proteico sin Ig anti-ADM para su utilización en tratamientos
CN105102985B (zh) *	2013-03-20	2018-05-18	斯弗因高泰克有限公司	用于指导血压下降疗法的肾上腺髓质素
WO2018216580A1 (fr) *	2017-05-22	2018-11-29	東ソー株式会社	Procédé de fourniture d'informations de prédiction de pronostic sur la base d'une fluctuation de concentration d'adrénomédulline et réactif associé

2017
- 2017-07-07 US US16/315,805 patent/US20190376985A1/en active Pending
- 2017-07-07 CA CA3030214A patent/CA3030214A1/fr active Pending
- 2017-07-07 EP EP17740693.1A patent/EP3482208B1/fr active Active
- 2017-07-07 WO PCT/EP2017/067091 patent/WO2018007588A1/fr unknown
- 2017-07-07 AU AU2017294549A patent/AU2017294549C1/en active Active
- 2017-07-07 CN CN201780055476.7A patent/CN109716136B/zh active Active
- 2017-07-07 SG SG11201900133WA patent/SG11201900133WA/en unknown
- 2017-07-07 MX MX2019000003A patent/MX2019000003A/es unknown
- 2017-07-07 ES ES17740693T patent/ES2948446T3/es active Active
- 2017-07-07 EP EP23167412.8A patent/EP4231018A3/fr not_active Withdrawn
- 2017-07-07 RU RU2019103403A patent/RU2019103403A/ru unknown
- 2017-07-07 JP JP2019500262A patent/JP7191813B2/ja active Active
- 2017-07-07 BR BR112019000199-9A patent/BR112019000199A2/pt unknown
2022
- 2022-05-25 JP JP2022085204A patent/JP7654597B2/ja active Active
2024
- 2024-06-18 JP JP2024098031A patent/JP2024163910A/ja active Pending

Also Published As

Publication number	Publication date
AU2017294549B2 (en)	2023-04-20
CA3030214A1 (fr)	2018-01-11
EP4231018A2 (fr)	2023-08-23
AU2017294549A1 (en)	2019-01-24
WO2018007588A1 (fr)	2018-01-11
AU2017294549C1 (en)	2023-10-26
EP4231018A3 (fr)	2023-11-15
JP2019530851A (ja)	2019-10-24
RU2019103403A (ru)	2020-08-10
JP2024163910A (ja)	2024-11-22
US20190376985A1 (en)	2019-12-12
ES2948446T3 (es)	2023-09-12
MX2019000003A (es)	2019-08-29
BR112019000199A2 (pt)	2019-04-16
CN109716136A (zh)	2019-05-03
CN109716136B (zh)	2023-09-22
JP7654597B2 (ja)	2025-04-01
EP3482208A1 (fr)	2019-05-15
EP3482208B1 (fr)	2023-04-12
JP7191813B2 (ja)	2022-12-19
RU2019103403A3 (fr)	2020-10-01
JP2022122924A (ja)	2022-08-23

Publication	Publication Date	Title
SG11201900133WA (en)	2019-02-27	Adrenomedullin for assessing congestion in a subject with acute heart failure
SG11201809252YA (en)	2018-11-29	Methods for determining dpp3 and therapeutic methods
SG11201808152PA (en)	2018-10-30	Dna antibody constructs and method of using same
SG11201808820QA (en)	2018-11-29	Methods and kits for the diagnosis and risk stratification of patients with ischemia
SG11201900468YA (en)	2019-02-27	Anti- gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof
SG11201804086VA (en)	2018-06-28	Methods and compositions for nucleic acid analysis
SG11201809620UA (en)	2018-11-29	The contorsbody - a single chain target binder
SG11201803666WA (en)	2018-06-28	Single image detection
SG11201900975XA (en)	2019-03-28	Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same
SG11201805422WA (en)	2018-07-30	Multivalent and multispecific ox40-binding fusion proteins
SG11201907208XA (en)	2019-09-27	Radiolabeled anti-lag3 antibodies for immuno-pet imaging
SG11201806639VA (en)	2018-09-27	New streptococcal proteases
SG11201807501UA (en)	2018-09-27	Method and system for imaging
SG11201805579SA (en)	2018-08-30	Recombinant igg fc multimers
SG11201908238SA (en)	2019-10-30	Anti-c5 antibodies and uses thereof
SG11201408092UA (en)	2015-01-29	Endoprosthesis and delivery device for implanting such endoprosthesis
SG11201810420YA (en)	2018-12-28	Antibodies to alpha-synuclein and uses thereof
SG11201809789SA (en)	2018-12-28	Dna monoclonal antibodies targeting checkpoint molecules
SG11201805496PA (en)	2018-07-30	An immunoassay for the diagnosis of viral infections
SG11201900992XA (en)	2019-03-28	Computer architecture and method for recommending asset repairs
SG11201803642WA (en)	2018-06-28	Bacteria-based protein delivery
SG11201810429UA (en)	2018-12-28	Anti-cd19 antibody formulations
SG11201909882SA (en)	2019-11-28	Targeted neoepitope vectors and methods therefor
SG11201907199QA (en)	2019-09-27	Cancer treatment
SG11201806432PA (en)	2018-08-30	Methods for assessing risk of developing colorectal cancer